Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Charbit

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The Journal of Allergy and Clinical Immunology|August 25, 2016
Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 childrenMarie-Louise Frémond, Mathieu Paul Rodero, Nadia Jeremiah, et al.
Science (New York, N.Y.)|July 15, 2020
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientsJérôme Hadjadj, Nader Yatim, Laura Barnabei, et al.
Immunity & Ageing : I & A|May 7, 2024
Increased levels of GM-CSF and CXCL10 and low CD8<sup>+</sup> memory stem T Cell count are markers of immunosenescence and severe COVID-19 in older peopleJohanne Poisson, Carine El-Sissy, Arnaud Serret-Larmande, et al.
Med (New York, N.Y.)|August 20, 2021
A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditisCamille de Cevins, Marine Luka, Nikaïa Smith, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The Journal of Allergy and Clinical Immunology|August 25, 2016
Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 childrenMarie-Louise Frémond, Mathieu Paul Rodero, Nadia Jeremiah, et al.
Science (New York, N.Y.)|July 15, 2020
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientsJérôme Hadjadj, Nader Yatim, Laura Barnabei, et al.
Immunity & Ageing : I & A|May 7, 2024
Increased levels of GM-CSF and CXCL10 and low CD8<sup>+</sup> memory stem T Cell count are markers of immunosenescence and severe COVID-19 in older peopleJohanne Poisson, Carine El-Sissy, Arnaud Serret-Larmande, et al.
Med (New York, N.Y.)|August 20, 2021
A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditisCamille de Cevins, Marine Luka, Nikaïa Smith, et al.
Pageof 4